Graham Peter  Lidgard net worth and biography

Graham Lidgard Biography and Net Worth

Insider of Exact Sciences
Graham Lidgard is the co-inventor of Cologuard®, and has served as our Chief Science Officer since 2009. Prior to joining Exact Sciences, he served as Vice President, Research and Development at Nanogen, Inc., Vice President, Research and Development at Gen-Probe, Inc., and Co-founder and Vice President, Product Development at Matritech, Inc. Mr. Lidgard holds a bachelor’s degree with honors as well as a doctoral degree from the University of Manchester.

What is Graham Peter Lidgard's net worth?

The estimated net worth of Graham Peter Lidgard is at least $2.54 million as of March 2nd, 2021. Mr. Lidgard owns 48,014 shares of Exact Sciences stock worth more than $2,540,421 as of November 23rd. This net worth evaluation does not reflect any other assets that Mr. Lidgard may own. Learn More about Graham Peter Lidgard's net worth.

How do I contact Graham Peter Lidgard?

The corporate mailing address for Mr. Lidgard and other Exact Sciences executives is 5505 ENDEAVOR LANE, MADISON WI, 53719. Exact Sciences can also be reached via phone at (608) 284-5700 and via email at [email protected]. Learn More on Graham Peter Lidgard's contact information.

Has Graham Peter Lidgard been buying or selling shares of Exact Sciences?

Graham Peter Lidgard has not been actively trading shares of Exact Sciences during the past quarter. Most recently, Graham Peter Lidgard sold 11,735 shares of the business's stock in a transaction on Friday, March 5th. The shares were sold at an average price of $121.33, for a transaction totalling $1,423,807.55. Learn More on Graham Peter Lidgard's trading history.

Who are Exact Sciences' active insiders?

Exact Sciences' insider roster includes Brian Baranick (Insider), Sarah Condella (SVP), Kevin Conroy (CEO), D. Coward (Insider), Everett Cunningham (Insider), James Doyle (Director), Jeffrey Elliott (CFO), James Herriott (General Counsel), Torsten Hoof (Insider), Daniel Levangie (Director), Graham Lidgard (Insider), Jacob Orville (Insider), and Katherine Zanotti (Director). Learn More on Exact Sciences' active insiders.

Are insiders buying or selling shares of Exact Sciences?

In the last twelve months, Exact Sciences insiders bought shares 1 times. They purchased a total of 19,500 shares worth more than $1,001,325.00. In the last twelve months, insiders at the medical research company sold shares 36 times. They sold a total of 77,348 shares worth more than $4,737,043.93. The most recent insider tranaction occured on November, 13th when CEO Kevin T Conroy bought 19,500 shares worth more than $1,001,325.00. Insiders at Exact Sciences own 1.4% of the company. Learn More about insider trades at Exact Sciences.

Information on this page was last updated on 11/13/2024.

Graham Peter Lidgard Insider Trading History at Exact Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/5/2021Sell11,735$121.33$1,423,807.55View SEC Filing Icon  
3/2/2021Sell2,524$138.42$349,372.0848,014View SEC Filing Icon  
2/24/2021Sell5,842$136.30$796,264.6047,171View SEC Filing Icon  
11/7/2018Sell38,311$75.01$2,873,708.1129,398View SEC Filing Icon  
11/5/2018Sell37,613$75.01$2,821,351.1329,398View SEC Filing Icon  
11/1/2018Sell79,673$71.73$5,714,944.29124,528View SEC Filing Icon  
10/8/2018Sell58,000$69.36$4,022,880.00204,684View SEC Filing Icon  
3/9/2018Sell6,125$50.94$312,007.50200,074View SEC Filing Icon  
2/28/2018Sell39,884$43.10$1,719,000.40View SEC Filing Icon  
12/1/2017Sell45,770$58.27$2,667,017.90237,820View SEC Filing Icon  
11/1/2017Sell45,775$53.60$2,453,540.00272,819View SEC Filing Icon  
10/2/2017Sell81,025$47.16$3,821,139.00366,519View SEC Filing Icon  
9/5/2017Sell75,683$40.81$3,088,623.23308,377View SEC Filing Icon  
9/1/2017Sell45,775$41.49$1,899,204.75288,952View SEC Filing Icon  
2/27/2017Sell8,668$21.51$186,448.68314,527View SEC Filing Icon  
7/26/2016Sell7,383$14.82$109,416.06227,592View SEC Filing Icon  
3/10/2016Sell3,041$6.05$18,398.05228,170View SEC Filing Icon  
2/25/2016Sell2,997$5.52$16,543.44222,742View SEC Filing Icon  
2/23/2016Sell2,411$6.39$15,406.29216,903View SEC Filing Icon  
2/26/2015Sell3,938$23.44$92,306.72View SEC Filing Icon  
2/24/2015Sell4,037$22.90$92,447.30View SEC Filing Icon  
1/2/2015Sell3,363$26.72$89,859.36View SEC Filing Icon  
10/29/2014Sell8,015$24.68$197,810.20View SEC Filing Icon  
7/25/2014Sell11,081$15.99$177,185.19View SEC Filing Icon  
2/24/2014Sell3,160$14.07$44,461.20106,214View SEC Filing Icon  
1/2/2014Sell10,288$11.96$123,044.48102,149View SEC Filing Icon  
10/28/2013Sell7,430$11.07$82,250.10View SEC Filing Icon  
See Full Table

Graham Peter Lidgard Buying and Selling Activity at Exact Sciences

This chart shows Graham Peter Lidgard's buying and selling at Exact Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Exact Sciences Company Overview

Exact Sciences logo
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Read More

Today's Range

Now: $52.91
Low: $52.79
High: $54.26

50 Day Range

MA: $64.79
Low: $49.33
High: $71.93

2 Week Range

Now: $52.91
Low: $40.62
High: $79.62

Volume

2,004,102 shs

Average Volume

2,642,613 shs

Market Capitalization

$9.79 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27